Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Biotechnology

Healthcare
$0.69 -3.42%

-$0.04 today

Market cap
$50.84M
Beta
-0.24
P/E (TTM)
-3.8
EPS (TTM)
-$0.27
52W Low $0.89High $2.09

Volume 0.17M

Average 0.13M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$3.69M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$9.71M

FY 2025 · Annual

+53.2% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Depreciation & Amortization0004.34M0
Deferred Income Tax00000
Stock-Based Compensation0006.87M5.29M
Change in Working Capital18.74K385.49K113.84K126.47K594.69K
Accounts Receivables00000
Inventory00000
Accounts Payables18.74K0114.56K183.63K(50.77K)
Other Working Capital18.74K385.49K(713)(57.16K)645.46K
Other Non-Cash Items0385.49K9.1M130K840K
Operating Cash Flow(119.4K)(468.66K)(3.86M)(5.07M)(3.69M)
Capital Expenditures(4)0(4)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment0462.39K3.17M(101K)0
Common Stock Issued001M6.83M9.55M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities119.4K7.69K(310.38K)(396.65K)155.52K
Financing Cash Flow119.4K470.08K3.86M6.34M9.71M
Effect of Forex Changes00000
Net Change in Cash01.42K(188)1.26M6.02M
Free Cash Flow(119.4K)(468.66K)(3.86M)(5.07M)(3.69M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$10.4M
+ D&A$0
+ Stock-Based Comp$5.3M
+ Deferred Tax$0
+ Working Capital$594.7K
+ Other Non-Cash$840.0K
= Operating Cash Flow-$3.7M
- Capex$0
= Free Cash Flow-$3.7M

Analysis

FY2025 free cash flow is -$3.7M. FCF conversion is 35.4% of net income. Operating cash flow was -$3.7M, with capex of $0. The largest bridge item is Stock-Based Comp at $5.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3S-3 filingOct 27, 2026
8-KCurrent reportOct 6, 2026
8-KCurrent reportSep 17, 2026
8-KCurrent reportSep 16, 2026
8-KCurrent reportSep 14, 2026

Does TELO generate free cash flow?

Telomir Pharmaceuticals, Inc. Common Stock (TELO) generated -$3.69M of free cash flow in fiscal 2025.

How much operating cash flow does TELO produce?

Operating cash flow was -$3.69M, before capital expenditures of $0.00.